Turner NC - Search Results

1

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A. Iorns E, et al. Among authors: turner nc. Cancer Cell. 2008 Feb;13(2):91-104. doi: 10.1016/j.ccr.2008.01.001. Cancer Cell. 2008. PMID: 18242510 Free article.

2

Hallmarks of 'BRCAness' in sporadic cancers.

Turner N, Tutt A, Ashworth A. Turner N, et al. Nat Rev Cancer. 2004 Oct;4(10):814-9. doi: 10.1038/nrc1457. Nat Rev Cancer. 2004. PMID: 15510162 Review.

3

Targeting the DNA repair defect of BRCA tumours.

Turner N, Tutt A, Ashworth A. Turner N, et al. Curr Opin Pharmacol. 2005 Aug;5(4):388-93. doi: 10.1016/j.coph.2005.03.006. Curr Opin Pharmacol. 2005. PMID: 15955736 Review.

4

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A. Tutt AN, et al. Cold Spring Harb Symp Quant Biol. 2005;70:139-48. doi: 10.1101/sqb.2005.70.012. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869747

5

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. McCabe N, et al. Among authors: turner nc. Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140. Cancer Res. 2006. PMID: 16912188

6

Basal-like breast cancer and the BRCA1 phenotype.

Turner NC, Reis-Filho JS. Turner NC, et al. Oncogene. 2006 Sep 25;25(43):5846-53. doi: 10.1038/sj.onc.1209876. Oncogene. 2006. PMID: 16998499 Review.

7

BRCA1 dysfunction in sporadic basal-like breast cancer.

Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN. Turner NC, et al. Oncogene. 2007 Mar 29;26(14):2126-32. doi: 10.1038/sj.onc.1210014. Epub 2006 Oct 2. Oncogene. 2007. PMID: 17016441

8

FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.

Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, Weber B, Hardisson D, Schmitt FC, Palacios J, Lakhani SR, Ashworth A. Reis-Filho JS, et al. Among authors: turner nc. Clin Cancer Res. 2006 Nov 15;12(22):6652-62. doi: 10.1158/1078-0432.CCR-06-1164. Clin Cancer Res. 2006. PMID: 17121884

9

Utilizing RNA interference to enhance cancer drug discovery.

Iorns E, Lord CJ, Turner N, Ashworth A. Iorns E, et al. Nat Rev Drug Discov. 2007 Jul;6(7):556-68. doi: 10.1038/nrd2355. Nat Rev Drug Discov. 2007. PMID: 17599085 Review.

10

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A. Turner NC, et al. EMBO J. 2008 May 7;27(9):1368-77. doi: 10.1038/emboj.2008.61. Epub 2008 Apr 3. EMBO J. 2008. PMID: 18388863 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

274 results

Search Page